Sign In
Buy FLXN
$25.10
-0.0069 (-0.0275%)
At Close: Jun 22, 2026
Edited Transcript of FLXN earnings conference call or presentation 7-May-20 8:30pm GMT
08:14pm, Friday, 08'th May 2020
Q1 2020 Flexion Therapeutics Inc Earnings Call
Needham Maintains Buy on Flexion Therapeutics, Lowers Price Target to $20
02:49pm, Friday, 08'th May 2020Captains of industry go cap in hand for the arts
02:11pm, Friday, 08'th May 2020
Australia's performing arts scene faces an existential crisis that philanthropy alone can't solve, say three chairmen of Australia's major companies.
RBC Capital Maintains Outperform on Flexion Therapeutics, Lowers Price Target to $18
01:13pm, Friday, 08'th May 2020U.S. RESEARCH ROUNDUP-Becton Dickinson, Epam Systems, PayPal Holdings
11:36am, Friday, 08'th May 2020
Wall Street securities analysts on Friday revised their ratings and price targets on several
U.S.-listed companies, including Becton Dickinson, Epam Systems and PayPal Holdings.
HIGHLIGHTS
Flexion Therapeutics Q1 EPS $(0.950) Beats $(0.990) Estimate, Sales $20.127M Beat $19.800M Estimate
09:51pm, Thursday, 07'th May 2020Flexion Therapeutics Reports First-Quarter 2020 Financial Results and Recent Business Highlights
08:01pm, Thursday, 07'th May 2020
Flexion Therapeutics, Inc. (FLXN) today reported financial results and recent business highlights for the quarter ended March 31, 2020. “We were very pleased with ZILRETTA’s trajectory earlier in
The Daily Biotech Pulse: FDA Approves Novartis Lung Cancer Drug, 2-Way Contest Emerging For Tetraphase Pharma, Dexcom To Join S&P 500
12:00am, Thursday, 07'th May 2020
Here's a roundup of top developments in the biotech space over the last 24 hours:
Scaling The Peaks
(Biotech stocks hitting 52-week highs May 6.)
Adverum Biotechnologies Inc...
Flexion Therapeutics, Inc. (FLXN) will present positive data from two studies of FX201, an investigational gene therapy for osteoarthritis (OA), at the American Society of Gene and Cell Therapy (ASGCT
The Week Ahead In Biotech: Smid-Cap Earnings News Flow Picks Up Pace
12:00am, Sunday, 03'rd May 2020
Biotech stocks started last week on a strong note but the upward momentum slowed through the week. The week saw a slew of earnings from big pharma names, including Merck...
Flexion Therapeutics (NASDAQ:FLXN) Stock Price Down 9.8% on Analyst Downgrade
06:56am, Saturday, 02'nd May 2020
Flexion Therapeutics Inc (NASDAQ:FLXN) fell 9.8% during trading on Friday after Needham & Company LLC lowered their price target on the stock from $36.00 to $30.00. Needham & Company LLC currently has
Flexion Therapeutics Announces Publication of New Abstracts Accepted at Osteoarthritis Research Society International OARSI 2020
01:00pm, Friday, 01'st May 2020
Flexion Therapeutics, Inc. (FLXN) today announced the publication of data from two new analyses of patients treated with ZILRETTA (triamcinolone acetonide injectable suspension), including an analysis
Northland Securities Remains a Buy on Opiant Pharmaceuticals (OPNT)
11:00am, Friday, 01'st May 2020
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on Opiant Pharmaceuticals (OPNT), with a price target of $42.00.
Northland Securities Remains a Buy on Opiant Pharmaceuticals (OPNT)
11:00am, Friday, 01'st May 2020
In a report released today,
Carl Byrnes
from Northland Securities maintained a
Buy
rating on Opiant Pharmaceuticals (
OPNT
–
Research Report
), with a price target of
$42.00
. The company’s shares
